SIGLEC1 and cancer: Since the infiltration of CD8+ lymphocytes in tumor tissue indicates an anti-cancer immune response, we determined CD8+ cell density in tumors, compared it to that of CD169+ macrophages in matched RLN tissues, and further determined its correlation with clinicopathological factors.